Stock YS YS BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages YS Biopharma Co., Ltd.

Equities

YS

KYG9845F1090

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-22 EDT 		5-day change 1st Jan Change
0.9189 USD -6.23% Intraday chart for YS Biopharma Co., Ltd. -10.79% +79.82%
04-19 YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023 CI
04-18 YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of Pika Rabies Vaccine
YS Biopharma Co., Ltd. Announces Board Changes
YS Biopharma Co., Ltd. Announces Board Changes
YS Biopharma Co., Ltd. Announces Board Resignations
YS Biopharma Co., Ltd. Announces Chief Executive Officer Changes
YS Biopharma Co., Ltd. Announces Management Changes
YS Biopharma Receives a Notice from APEX Prospect Limited
YS Biopharma Co., Ltd. Announces Appointment of New Directors
Ys Biopharma Co., Ltd. Announces Board Resignations
YS Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2023
YS Biopharma Co., Ltd. Appoints Rui Yu as Chairperson of Its Audit Committee, as Member of Its Compensation Committee, and as Member of the Nominating and Corporate Governance Committee
YS Biopharma Co., Ltd. Announces Board Changes
YS Biopharma Co., Ltd. Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
YS Biopharma Enrolls 1st Subject in Late-Stage Rabies Vaccine Clinical Trial; Shares Rise
YS Biopharma Co., Ltd. Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine
YS Biopharma Says it Obtained US Patent for Immunotherapy Targeting Chronic Hepatitis B; Shares Gain Pre-Bell
Ys Biopharma Co., Ltd. Grants Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection
Sector Update: Health Care Stocks Climbing Late Afternoon
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. YS Stock
  4. News YS Biopharma Co., Ltd.
  5. Other languages